Peptides News and Research

RSS

BioDiem signs agreement with RMIT to create new non-influenza vaccines

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem’s live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem’s strategy, and this research is part of the work towards that goal.

19 Jul 2012

Diabetes linked to onset of Alzheimer's disease

Researchers from the University of Medicine and Dentistry of New Jersey (UMDNJ), collaborating with scientists from Northwestern University in Illinois, have provided direct experimental evidence that diabetes is linked to the onset of Alzheimer's disease.

19 Jul 2012

Study focuses on interaction between two key proteins involved in apoptosis

A promising method for promoting programmed cell death (apoptosis) developed by researchers at the Hebrew University of Jerusalem and the Weizmann Institute of Science paves the way for a possible novel therapy to target cancer cells.

18 Jul 2012

Novel technique can cause apoptosis of cancer cells

Researchers from the Hebrew University of Jerusalem and the Weizmann Institute of Science have developed a technique to cause apoptosis, or programmed cell death, that could lead to new approaches to treating cancer.

18 Jul 2012

Heart-protective protein finally found

It is a cellular component so scarce, some scientists even doubted its existence, and many others gave up searching for its molecular structure. Now a team led by researchers at Johns Hopkins has defined the protein structural composition of mitoKATP, a potassium channel in the mitochondria of the heart and other organs that is known to protect against tissue damage due to a heart attack or stroke.

18 Jul 2012

Johnson & Johnson second quarter sales decrease 0.7% to $16.5B

Johnson & Johnson today announced sales of $16.5 billion for the second quarter of 2012, a decrease of 0.7% as compared to the second quarter of 2011. Operational results increased 3.5% and the negative impact of currency was 4.2%.

17 Jul 2012

Merck to present results from clinical studies on BACE inhibitors at AAIC 2012

Merck, known as MSD outside the United States and Canada, announced today presentations at the upcoming Alzheimer's Association International Conference (AAIC) being held in Vancouver, British Columbia, Canada on July 14-19, 2012.

16 Jul 2012

Scientists uncover new strategy that may help reverse mucus dehydration in CF, COPD

University of North Carolina scientists have uncovered a new strategy that may one day help people with cystic fibrosis and chronic obstructive pulmonary disorder better clear the thick and sticky mucus that clogs their lungs and leads to life-threatening infections.

16 Jul 2012

Arrowhead initiates Adipotide Phase 1 trial in obesity

Arrowhead Research Corporation, a targeted therapeutics company, today announced that the first patient has been dosed in a Phase 1 clinical trial with Adipotide, a new class of treatment for obesity.

11 Jul 2012

ACADI’s pimavanserin may have therapeutic benefits in treatment of ADP

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced results of preclinical studies, which suggest that pimavanserin, ACADIA's proprietary product candidate currently in Phase III development for Parkinson's disease psychosis, also may have therapeutic benefits in the treatment of Alzheimer's disease psychosis (ADP).

10 Jul 2012

Researchers develop new silk-based stabilizer for vaccines and antibiotics

Researchers funded by the National Institutes of Health have developed a new silk-based stabilizer that, in the laboratory, kept some vaccines and antibiotics stable up to temperatures of 140 degrees Fahrenheit.

10 Jul 2012

Oligomers may be responsible for onset of Alzheimer's

Alzheimer's disease is one of the most dreaded and debilitating illnesses one can develop. Currently, the disease afflicts 6.5 million Americans and the Alzheimer's Association projects it to increase to between 11 and 16 million, or 1 in 85 people, by 2050.

10 Jul 2012

Roux-en-Y gastric bypass surgery induces changes in the gut microbiota

Research to be presented at the Annual Meeting of the Society for the Study of Ingestive Behavior (SSIB), the foremost society for research into all aspects of eating and drinking behavior, finds that gastric bypass surgery induces changes in the gut microbiota and peptide release that are similar to those seen after treatment with prebiotics.

10 Jul 2012

Researchers use metal complexes to modify peptide hormones

Researchers at the RUB and from Berkeley have used metal complexes to modify peptide hormones. In the Journal of the American Chemical Society, they report for the first time on the three-dimensional structure of the resulting metal-peptide compounds.

9 Jul 2012

Novel treatment for cancer based on protein from HIV-1 virus

Yissum, Research and Development Company of the Hebrew University of Jerusalem, introduces a novel method for treating cancer based on Vif, a protein isolated from the Human Immunodeficiency Virus (HIV-1). The method was invented by Professor Emeritus Moshe Kotler and Dr. Roni Nowarski from the Department of Immunology and Cancer Research at the Hebrew University.

9 Jul 2012

New somatostatin vaccines promote weight loss

New vaccines promote weight loss. A new study, published in BioMed Central's open access journal, Journal of Animal Science and Biotechnology, assesses the effectiveness of two somatostatin vaccinations, JH17 and JH18, in reducing weight gain and increasing weight loss in mice.

9 Jul 2012

Biological mechanisms behind appetite-suppressing effects of proteins

Frequently recommended in weight-loss diets, dietary proteins have proven effectiveness thanks to their appetite-suppressing effects. A team led by Gilles Mithieux, Director of Inserm's Unit 855 "Nutrition and the Brain" in Lyon, has managed to explain the biological mechanisms behind these properties.

7 Jul 2012

ADCT, CRT sign agreements to develop ADCs against cancer

Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, and Switzerland-based ADC Therapeutics Sarl (ADCT) announce today that they have signed agreements to develop cancer treatments called Antibody Drug Conjugates (ADCs) using CRT antibodies and peptides, and ADCT's 'warhead' and linker chemistries.

6 Jul 2012

Peptides block MORs and curb appetite

Feeling full involves more than just the uncomfortable sensation that your waistband is getting tight. Investigators reporting online on July 5th in the Cell Press journal Cell have now mapped out the signals that travel between your gut and your brain to generate the feeling of satiety after eating a protein-rich meal. Understanding this back and forth loop between the brain and gut may pave the way for future approaches in the treatment and/or prevention of obesity.

6 Jul 2012

Extensive health benefits associated with milk consumption

Milk is designed by nature as a complete food. Its composition has evolved with each mammalian species to reflect the particular environmental conditions and evolutionary demands of the young of that species. Humans have exploited this valuable resource since the dawn of the agricultural revolution through domestication of animals, in particular the cow. We have developed the technology to preserve milk during times of abundance and this has resulted in an array of foods now common in the diets of most human cultures.

4 Jul 2012